Person:
GÜNEŞ, BEGÜM

Loading...
Profile Picture
Status
Kurumdan Ayrılmıştır
Organizational Units
Organizational Unit
Job Title
First Name
BEGÜM
Last Name
GÜNEŞ
Name
Email Address
Birth Date

Search Results

Now showing 1 - 4 of 4
Loading...
Thumbnail Image
PublicationOpen Access

Which dermatology patients attend to Dermatology Outpatient Clinics during the SARS-CoV-2 outbreak in Turkey and what happened to them?

2020-05-11T04:00:00Z, CENGİZ, Fatma Pelin, EMİROĞLU, Nazan, BAHALI, ANIL GÜLSEL, DİZMAN, DİDEM, TAŞLIDERE, NAZAN, MERT, Ömer, Akarslan, Tahsin Cagdas, Gunes, Begum, KÜÇÜK, Özlem Su, ONSUN, Nahide, CENGİZ, FATMA PELIN, EMİROĞLU, NAZAN, BAHALI, ANIL GÜLSEL, DİZMAN, DİDEM, TAŞLIDERE, NAZAN, GÜNEŞ, BEGÜM, MERT, ÖMER, SU KÜÇÜK, ÖZLEM, ONSUN, NAHIDE

Coronavirus disease, first emerged in Wuhan, rapidly spread all over the world since December 2019. There are concerns about elective dermatology appointments and its results. Herein, we aimed to find out which type of dermatologic patients attended to dermatology outpatient clinic. The patients visiting the clinics for elective dermatologic diseases between March 11 and 18, 2020, were included in this study. Their age, sex, diagnosis of disease, requirement for emergent intervention, and their medical records about COVID-19 were obtained. There were 390 patients attending to the dermatology outpatient clinic in this period. The most common disease was acne (N: 94, 24%), only 19% of patients need emergent interventions or dose adjustment. There were 40 (10%) patients over the age of 65. After their visits, five patients were diagnosed as COVID-19 in 2weeks. Dermatologic examinations may be a vector for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission since being closed to the patient. Five of our patients were diagnosed as COVID-19 after their elective visit to hospital. Since the asymptomatic course of some young patients, most of our patients were not screened for COVID-19. Our findings support the concerns of elective physician examinations.

No Thumbnail Available
PublicationMetadata only

Demographic characteristics, treatment, and outcome of patients with Kaposi sarcoma: Ten-year follow-up results of a single center

2021-09-01T00:00:00Z, GÜNEŞ, BEGÜM, MERT, Ömer, ONSUN, Nahide, GÜNEŞ, BEGÜM, MERT, ÖMER, ONSUN, NAHIDE

Background Clinical features, types of Kaposi sarcoma, and treatment outcomes have not been well-defined in Turkey. In this study, we reviewed records of the patients who had been diagnosed with Kaposi sarcoma in the last decade in a single center and evaluated treatment results. Methods Medical records of the Kaposi sarcoma patients seen in the last decade in a single tertiary center were evaluated in detail. Results A total of 27 patients were identified; 18 patients had been checked for HHV8; and 16 of those patients were positive for HHV8. One patient was positive for HIV. Two patients having mycosis fungoides and myasthenia graves developed iatrogenic KS after immunosuppressive treatments. Interferon alpha was used in 21 patients; 8 patients achieved complete response; and 11 patients achieved a partial response. No serious side effects were observed. Systemic involvement did not develop in any patients except lymph node involvement in a patient with widespread skin lesions.

Loading...
Thumbnail Image
PublicationOpen Access

A generalized pustular psoriasis flare after CoronaVac COVID-19 vaccination: Case report

2021-01-01T00:00:00Z, ONSUN, Nahide, KAYA, GÖKHAN, IŞIK, BENGİSU GÜÇKAN, GÜNEŞ, BEGÜM, ONSUN, NAHIDE, KAYA, GÖKHAN, IŞIK, BENGİSU GÜÇKAN, GÜNEŞ, BEGÜM

CoronoVac is a non-viable vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Nowadays, there has been vaccination program for at-risk groups and older adults in Turkey. We here present 72-year-old male psoriasis patient who developed generalized pustular psoriasis flare after administration of CoronoVac. The COVID-PCR test was negative and investigations for flare etiology were all normal. He was first (to the best of our knowledge) psoriasis patient who developed an erythrodermic flare after the first dose of CoronaVac vaccine.

Loading...
Thumbnail Image
PublicationOpen Access

Retention and survival rate of etanercept in psoriasis over 15 years and patient outcomes during the COVID-19 pandemic: The real-world experience of a single center

2020-12-01T00:00:00Z, GÜNEŞ, BEGÜM, ONSUN, Nahide, YABACI, AYŞEGÜL, ONSUN, NAHIDE, GÜNEŞ, BEGÜM, YABACI TAK, AYŞEGÜL

There have been a number of investigations of the efficacy and safety of etanercept. This study was performed to obtain long-term drug survival data (ie, time to drug discontinuation) for etanercept, and the reasons for its discontinuation. The study population consisted of patients with psoriatic arthritis and psoriasis followed up by our clinic, registered in the Turkish Psoriasis Registry (PSR-TR) and treated with etanercept for at least 4 weeks between January 1, 2005, and January 31, 2020. The efficacy of etanercept was evaluated in terms of the Psoriasis Area and Severity Index (PASI) 75, PASI 90 and PASI 100 response rates at 12, 24, 36, and 48 weeks, and annually thereafter. The behaviors of the patients with respect to the use of etanercept, and the outcomes of those who continued to use it during the COVID-19 pandemic, were also investigated.